sTNFR1

sTNFRr1 and sTNFR2 are predictive markers of Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD).

Elevations in circulating soluble tumor necrosis factor receptors 1 and 2 (sTNFR1 and 2) have been reported in a wide variety of clinical conditions including cancer, congestive heart failure, rheumatoid arthritis, neurological diseases and infection.

Recently, in studies conducted at the Joslin Diabetes Center, elevated circulating sTNFR1 levels were strongly associated with the subsequent development of advanced Diabetic Kidney Disease (DKD) in Type I and Type 2 diabetic patients.

These findings have been further validated in two additional cohorts by EKF Diagnostics.

The EKF Diagnostics Human sTNFR1 EIA is a 4.5 hour solid phase quantitative sandwich enzyme immunoassay. The test procedure is based on the sequential addition of sample, polyclonal anti-human sTNFR1 antibody-enzyme conjugate and colorimetric substrate to microplate wells coated with anti-human sTNFR1 monoclonal antibody.

The resultant colour intensity is proportional to the concentration of sTNFR1 in the test sample.

The assay is calibrated against a highly-purified E. coli-expressed recombinant human sTNFR1 protein corresponding to the N-terminal ectodomain. The calibration curve range is 7.8 500 pg/mL; this corresponds to serum / plasma sTNFR1 concentrations of 78 ­ 5000 pg/mL for samples assayed at 10-fold dilution. The assay range can be increased by increasing sample dilution.


Find out more about sTNFR and kidney disease